Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings

Core Viewpoint - Analysts project that BioMarin Pharmaceutical (BMRN) will report quarterly earnings of $0.57 per share, reflecting a 5.6% year-over-year increase, with revenues expected to reach $660.51 million, an 11% increase from the same quarter last year [1]. Revenue Estimates - The consensus for 'Revenues- Net product revenues' is projected at $648.62 million, indicating a 10.9% increase from the prior-year quarter [3]. - 'Revenues- Net Product Revenues- ALDURAZYME' is expected to be $35.01 million, showing a year-over-year decline of 13.1% [4]. - 'Revenues- Net Product Revenues- PALYNZIQ' is forecasted at $81.13 million, reflecting an 8.3% increase from the previous year [5]. - 'Revenues- Net Product Revenues- NAGLAZYME' is estimated at $106.25 million, indicating a 17.9% year-over-year increase [6]. - 'Revenues- Royalty and other revenues' is projected to be $11.90 million, representing a 12.5% increase year-over-year [9]. - 'Revenues- Net Product Revenues- BRINEURA' is expected to reach $42.14 million, indicating a 10.6% year-over-year increase [10]. - 'Revenues- Net Product Revenues- KUVAN' is forecasted at $31.18 million, reflecting a significant decline of 38.4% year-over-year [11]. - 'Revenues- Net Product Revenues- VIMIZIM' is projected to be $183.06 million, showing a 3.2% increase from the year-ago quarter [12]. - 'Revenues- Net Product Revenues- VOXZOGO' is expected to arrive at $165.51 million, indicating a substantial 46.1% increase from the previous year [13]. Stock Performance - BioMarin shares have increased by 2.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.4%, and the stock holds a Zacks Rank 3 (Hold), suggesting it will closely follow overall market performance [7].